Drug- and Disease-Specific Paradigms for Drug Delivery to the Central Nervous System

[1]  C. Wirtz,et al.  The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia—continuous selective intracarotid nimodipine therapy in awake patients without sedation , 2019, Neurosurgical Review.

[2]  H. R. Haynes,et al.  Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice , 2018, Annals of neurology.

[3]  A. Tosolini,et al.  Editorial: Gene Therapy for the Central and Peripheral Nervous System , 2018, Front. Mol. Neurosci..

[4]  R. Finkel,et al.  Nusinersen versus Sham Control in Later‐Onset Spinal Muscular Atrophy , 2018, The New England journal of medicine.

[5]  K. Aldape,et al.  Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Olson,et al.  Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry , 2017, CNS oncology.

[7]  Kwangmeyung Kim,et al.  Effect of high intensity focused ultrasound (HIFU) in conjunction with a nanomedicines‐microbubble complex for enhanced drug delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[8]  N. Lipsman,et al.  Current and emerging brain applications of MR-guided focused ultrasound , 2017, Journal of therapeutic ultrasound.

[9]  S. Tabrizi,et al.  Therapies targeting DNA and RNA in Huntington's disease , 2017, The Lancet Neurology.

[10]  L. Pereira de Almeida,et al.  Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[11]  B. Badie,et al.  Chimeric antigen receptor T-cell therapy for glioblastoma. , 2017, Translational research : the journal of laboratory and clinical medicine.

[12]  Shihua Li,et al.  CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease , 2017, The Journal of clinical investigation.

[13]  C. June,et al.  Immunotherapy for Brain Tumors. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Gradinaru,et al.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems , 2017, Nature Neuroscience.

[15]  R. Bellamkonda,et al.  Engineering challenges for brain tumor immunotherapy , 2017, Advanced drug delivery reviews.

[16]  J. Bruce,et al.  Convection-Enhanced Delivery , 2017, Neurotherapeutics.

[17]  G. Vlahović,et al.  Immunotherapy approaches in the treatment of malignant brain tumors , 2017, Cancer.

[18]  D. Hanley,et al.  Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial , 2017, The Lancet.

[19]  Richard Apps,et al.  Cytokine therapy‐mediated neuroprotection in a Friedreich's ataxia mouse model , 2017, Annals of neurology.

[20]  A. Mangraviti,et al.  Nanobiotechnology-based delivery strategies: New frontiers in brain tumor targeted therapies. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[21]  M. Isalan,et al.  Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice , 2016, Molecular Neurodegeneration.

[22]  P. Rancoita,et al.  Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial , 2016, The Lancet.

[23]  Patrick F. Sullivan,et al.  CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector , 2016, Molecular therapy. Nucleic acids.

[24]  B. Sullenger,et al.  Translation and Clinical Development of Antithrombotic Aptamers. , 2016, Nucleic acid therapeutics.

[25]  T. Mikkelsen,et al.  Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma , 2016, Science Translational Medicine.

[26]  W. Pardridge,et al.  CSF, blood-brain barrier, and brain drug delivery , 2016, Expert opinion on drug delivery.

[27]  T. Tominaga,et al.  Peri-tumoral leakage during intra-tumoral convection-enhanced delivery has implications for efficacy of peri-tumoral infusion before removal of tumor , 2016, Drug delivery.

[28]  R. Ouvrier,et al.  Outcome of Early Juvenile Onset Metachromatic Leukodystrophy After Unrelated Cord Blood Transplantation: A Case Series and Review of the Literature , 2016, Journal of child neurology.

[29]  E. Leuthardt,et al.  Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier , 2016, PloS one.

[30]  Chih-Kuang Yeh,et al.  Noninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson’s Disease , 2016, Scientific Reports.

[31]  E. Neuwelt,et al.  Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity , 2016, Journal of Neuro-Oncology.

[32]  A. Fabius,et al.  Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC , 2015, PloS one.

[33]  S. Sahoo,et al.  Therapeutic approaches of magnetic nanoparticles for the central nervous system. , 2015, Drug discovery today.

[34]  Chih-Kuang Yeh,et al.  Focused ultrasound-induced blood-brain barrier opening for non-viral, non-invasive, and targeted gene delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[35]  J. Bruce,et al.  Intraarterial drug delivery for glioblastoma mutiforme , 2015, Journal of Neuro-Oncology.

[36]  Seyed Nasrollah Tabatabaei,et al.  Remote control of the permeability of the blood-brain barrier by magnetic heating of nanoparticles: A proof of concept for brain drug delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[37]  A. Friedman,et al.  Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination. , 2015 .

[38]  Michael A Vogelbaum,et al.  Convection-enhanced delivery for the treatment of glioblastoma. , 2015, Neuro-oncology.

[39]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[40]  A. Luft,et al.  Intra-arterial administration of papaverine during mechanical thrombectomy for acute ischemic stroke. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[41]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[42]  W. Banks,et al.  Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. , 2014, Pharmacology & therapeutics.

[43]  X. Breakefield,et al.  Gene Therapy for the Nervous System: Challenges and New Strategies , 2014, Neurotherapeutics.

[44]  K. Gowthamarajan,et al.  Intranasal therapeutic strategies for management of Alzheimer’s disease , 2014, Journal of drug targeting.

[45]  Renad Alyautdin,et al.  Nanoscale drug delivery systems and the blood–brain barrier , 2014, International journal of nanomedicine.

[46]  J. Rossignol,et al.  Transplants of Adult Mesenchymal and Neural Stem Cells Provide Neuroprotection and Behavioral Sparing in a Transgenic Rat Model of Huntington's Disease , 2014, Stem cells.

[47]  E. Neuwelt,et al.  Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. , 2014, Advances in pharmacology.

[48]  R. E. Neal,et al.  In Vitro and Numerical Support for Combinatorial Irreversible Electroporation and Electrochemotherapy Glioma Treatment , 2014, Annals of Biomedical Engineering.

[49]  E. Castañón,et al.  Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study , 2013, Journal of Neuro-Oncology.

[50]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[51]  S. Martinez,et al.  Stem Cells from Wildtype and Friedreich’s Ataxia Mice Present Similar Neuroprotective Properties in Dorsal Root Ganglia Cells , 2013, PloS one.

[52]  P. Djupesland,et al.  Accessing the Brain: The Nose may Know the Way , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  Sanjay Singh,et al.  Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy. , 2013, BioImpacts : BI.

[54]  D. Ballon,et al.  Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench , 2012, Journal of Clinical Neuroscience.

[55]  N. Oku,et al.  Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[56]  R. Thorne,et al.  Intranasal delivery of biologics to the central nervous system. , 2012, Advanced drug delivery reviews.

[57]  M. Grinstaff,et al.  Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[58]  P. Starr,et al.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. , 2012, Human gene therapy.

[59]  Margaret S. Landis,et al.  Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. , 2012, Therapeutic delivery.

[60]  A. Fischman,et al.  CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder , 2012, PloS one.

[61]  M. Jayaraman,et al.  Intra-arterial therapy for acute stroke: trials and tribulations. , 2011, Medicine and health, Rhode Island.

[62]  X. Breakefield,et al.  Brain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System , 2011, Cellular and Molecular Neurobiology.

[63]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[64]  M. Bally,et al.  Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine , 2011, BMC Cancer.

[65]  José Weber Vieira de Faria,et al.  Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1-nitrosourea]. , 2010, Arquivos de neuro-psiquiatria.

[66]  Javed Ali,et al.  Strategy for effective brain drug delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[67]  Susan Chang,et al.  Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. , 2010, Neuro-oncology.

[68]  H. Brem,et al.  Combination of Intracranial Temozolomide With Intracranial Carmustine Improves Survival When Compared With Either Treatment Alone in a Rodent Glioma Model , 2010, Neurosurgery.

[69]  B. Engelhardt,et al.  The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.

[70]  Susan Bell,et al.  Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  K. Foust,et al.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes , 2009, Nature Biotechnology.

[72]  L. Hanson,et al.  Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease , 2008, BMC Neuroscience.

[73]  E. Wong,et al.  Bevacizumab reverses cerebral radiation necrosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  I. Ferrer,et al.  Immunotherapy for neurological diseases. , 2008, Clinical immunology.

[75]  S. Brodie,et al.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. , 2008, Ophthalmology.

[76]  Kullervo Hynynen,et al.  Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.

[77]  Kimberly A. Houser,et al.  Early disruptions of the blood–brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats , 2008, Neurobiology of Aging.

[78]  T. Ben-Hur,et al.  The changing face of neural stem cell therapy in neurologic diseases. , 2008, Archives of neurology.

[79]  N. Berman,et al.  Detrimental effects of aging on outcome from traumatic brain injury: a behavioral, magnetic resonance imaging, and histological study in mice. , 2008, Journal of Neurotrauma.

[80]  N. Laperriere,et al.  Gliadel wafers in the treatment of malignant glioma: a systematic review , 2007, Current oncology.

[81]  G. Rosenberg,et al.  Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. , 2007, Neurosurgical focus.

[82]  W. Mark Saltzman,et al.  New Methods for Direct Delivery of Chemotherapy for Treating Brain Tumors , 2006, The Yale journal of biology and medicine.

[83]  M. Byas-Smith,et al.  Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[84]  Z. Ram,et al.  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.

[85]  H. Brem,et al.  Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. , 2005, Anticancer research.

[86]  H. Newton.  Intra-arterial chemotherapy of primary brain tumors , 2005, Current treatment options in oncology.

[87]  Don L. Armstrong,et al.  Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease , 2005, Nature Medicine.

[88]  L. Maffei,et al.  Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[89]  K. Rejdak,et al.  [Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis]. , 2005, Neurologia i neurochirurgia polska.

[90]  L. Illum.  Is nose‐to‐brain transport of drugs in man a reality? , 2004, The Journal of pharmacy and pharmacology.

[91]  W. Mark Saltzman,et al.  Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.

[92]  K. Walter,et al.  Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  Z. Ram,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[94]  D. Murry,et al.  Clinical Pharmacology of Encapsulated Sustained-Release Cytarabine , 2000, The Annals of pharmacotherapy.

[95]  J. R. Reeves,et al.  Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model , 1999, British Journal of Cancer.

[96]  D. Groothuis,et al.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. , 2000, Neuro-oncology.

[97]  H Kalimo,et al.  Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.

[98]  H. Brem,et al.  Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model , 1995, International journal of cancer.

[99]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[100]  T. Friedmann.  A brief history of gene therapy , 1992, Nature Genetics.

[101]  N J Abbott,et al.  Electrical resistance across the blood‐brain barrier in anaesthetized rats: a developmental study. , 1990, The Journal of physiology.

[102]  I. Pastan,et al.  Immunotoxins , 1986, Cell.

[103]  N. Saunders,et al.  CSF-brain permeability in the immature sheep fetus: a CSF-brain barrier. , 1985, Brain research.

[104]  Charles Tator.  Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. , 1977, Surgical neurology.

[105]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[106]  A. Dayan,et al.  Postoperative intracavitary chemotherapy of malignant gliomas. A preliminary study using methotrexate. , 1973, Journal of neurosurgery.

[107]  S. Cooperband,et al.  Selective Destruction of Target Cells by Diphtheria Toxin Conjugated to Antibody Directed against Antigens on the Cells , 1970, Science.

[108]  T. Winship,et al.  Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. , 1950, Transactions of the ... Meeting of the American Surgical Association. American Surgical Association. Meeting.